


**Product Name** : SCR-1481B1  
**Cat. No.** : PC-23813  
**CAS No.** : 1174161-86-4  
**Molecular Formula** : C<sub>32</sub>H<sub>40</sub>ClF<sub>2</sub>N<sub>6</sub>O<sub>13</sub>P  
**Molecular Weight** : 821.12  
**Target** : Other Targets  
**Solubility** : 10 mM in DMSO



## Biological Activity

SCR-1481B1 (Metatinib anhydrous, Compound 68) is a specific small molecule inhibitor of gasdermin D (GSDMD) targeting the GSDMD N-terminal oligomerization interface I (MST KD=0.4 uM), exert pyroptosis inhibitory effects, also shows inhibition on Met activation VEGFR.

SCR-1481B1 (Metatinib anhydrous, Compound 68) significantly inhibited the release of LDH and IL-1 $\beta$  from iBMDM cells primed with LPS.

SCR-1481B1 (Metatinib anhydrous, Compound 68) specifically inhibit GSDMD N-terminal oligomerization.

SCR-1481B1 (Metatinib anhydrous, Compound 68) does not affect the cytotoxicity induced by GSDME N-terminal fragment and its oligomerization in HEK293T cells.

SCR-1481B1 (Metatinib anhydrous, Compound 68) specifically blocks GSDMD-mediated pyroptosis downstream of inflammasome activation.

SCR-1481B1 (Metatinib anhydrous, Compound 68) (10 mg/kg) significantly alleviate mouse sepsis in murine model of sepsis.

Combination SCR-1481B1 (Metatinib anhydrous, Compound 68) and PD-L1 antibody significantly enhances anti-tumor efficacy.

## References

Hu Y, et al. Cell Chem Biol. 2024 Dec 19;31(12):2024-2038.e7.

Patent WO 2009094417 A1

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com